Compare Xvivo Perfusion AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 7,516 Million (Small Cap)
122.00
NA
0.00%
-0.08
4.02%
3.42
Revenue and Profits:
Net Sales:
239 Million
(Quarterly Results - Jun 2026)
Net Profit:
16 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.28%
0%
-3.28%
6 Months
35.12%
0%
35.12%
1 Year
39.5%
0%
39.5%
2 Years
-45.35%
0%
-45.35%
3 Years
-12.95%
0%
-12.95%
4 Years
23.17%
0%
23.17%
5 Years
-35.41%
0%
-35.41%
Xvivo Perfusion AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
35.19%
EBIT Growth (5y)
47.44%
EBIT to Interest (avg)
14.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.37
Tax Ratio
32.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.10%
ROE (avg)
3.50%
Valuation key factors
Factor
Value
P/E Ratio
122
Industry P/E
Price to Book Value
4.12
EV to EBIT
94.18
EV to EBITDA
52.79
EV to Capital Employed
4.42
EV to Sales
10.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.69%
ROE (Latest)
3.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
239.00
178.30
34.04%
Operating Profit (PBDIT) excl Other Income
42.00
22.70
85.02%
Interest
0.00
10.40
-100.00%
Exceptional Items
0.00
0.30
-100.00%
Consolidate Net Profit
16.30
1.60
918.75%
Operating Profit Margin (Excl OI)
92.10%
34.80%
5.73%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 34.04% vs -15.22% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 918.75% vs -94.12% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
812.20
822.40
-1.24%
Operating Profit (PBDIT) excl Other Income
163.20
183.00
-10.82%
Interest
4.60
5.60
-17.86%
Exceptional Items
-2.60
-27.30
90.48%
Consolidate Net Profit
25.20
172.20
-85.37%
Operating Profit Margin (Excl OI)
114.50%
140.60%
-2.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.24% vs 37.64% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -85.37% vs 87.58% in Dec 2024
About Xvivo Perfusion AB 
Xvivo Perfusion AB
Pharmaceuticals & Biotechnology
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Company Coordinates 
Company Details
Massans gata 10 , GOETEBORG None : 412 51
Registrar Details






